How To Test For Platelet Function



Similar documents
Platelet Review July Thomas S. Kickler M.D. Johns Hopkins University School of Medicine

Platelet storage pool disease case discussions. Tzu-Fei Wang The Hemostasis and Thrombosis Center The Ohio State University

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY DEVICE AND INSTRUMENT TEMPLATE

Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.

Platelet Function analysis using Multiple Electrode Aggregometry (Multiplate )

Platelet Transmission Electron Microscopy and Flow Cytometry 11/15/2015

Screening Tests of Platelet Function: Update on their appropriate uses for diagnostic testing

Evaluation of the Patient with Suspected Platelet Refractory State

Hemostasis analyzer system

Multiplate platelet function analysis - application and interpretation

Rational for secondary prophylaxis in VWD

Embedding Point of Care monitoring (ROTEM) in daily practice

Learning Objectives. Qualitative and Quantitative Platelet Disorders. Platelet Signaling. Platelet vs. Coagulation Bleeding.

Point-of-care testing Thrombelastography and platelet transfusion

Easy Bruising and Bleeding in the Adult Patient: A Sign of Underlying Disease

The author has no disclosures

An Introduction to the Improved FDA Prescription Drug Labeling

ECG may be indicated for patients with cardiovascular risk factors

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

Note: Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS

An overview of CLL care and treatment. Dr Dean Smith Haematology Consultant City Hospital Nottingham

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function

Annals of West University of Timisoara

De effecten van Cofact op Rivaroxaban plasma in trombine generatie assays

Guidance for Industry and FDA Review Staff on Collection of Platelets by Automated Methods

Platelet Aggregation Testing in Platelet-Rich Plasma Description of Procedures With the Aim to Develop Standards in the Field

Recommendations: Other Supportive Therapy of Severe Sepsis*

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY

Management of the new antiplatelets and anticoagulants

Omega-3 fatty acids improve the diagnosis-related clinical outcome. Critical Care Medicine April 2006;34(4):972-9

C HAPTER 4 O RAL AND M AXILLOFACIAL S URGERY

ANESTHESIA FOR PATIENTS WITH CORONARY STENTS FOR NON CARDIAC SURGERY. Dr. Mahesh Vakamudi. Professor and Head

Whole Blood Flow Cytometry

Review of Newer Antiplatelets, Antithrombotics and Reversal

Immune Thrombocytopenic Purpura (ITP): A New Look at an Old Disorder

Grade 4 Thrombocytopenia During. Predictor of Response in Melanoma but Not in Renal Cell Cancer.

Predictive power. Multiplate analyzer

Indications 18 : PLATELET TRANSFUSION, ALLOIMMUNIZATION AND MANAGEMENT OF PLATELET REFRACTORINESS

The Monocyte Monolayer Assay (MMA): An Adjunct to Compatibility Testing

DATE: 06 May 2013 CONTEXT AND POLICY ISSUES

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

Strong bone for beautiful teeth Patient Information I Bone reconstruction with Geistlich Bio-Oss and Geistlich Bio-Gide

Is There A LIfe for DES after discontinuation of Clopidogrel

Issues and Challenges in ACS Management. Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW

INTRODUCTION Thrombophilia deep vein thrombosis DVT pulmonary embolism PE inherited thrombophilia

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

SARASOTA MEMORIAL HOSPITAL BLOOD COMPONENT CRITERIA AND INDICATIONS SCREENING GUIDELINES

Use of Novel Oral Anticoagulants (NOACs) and the new DAWN modules at Scripps

Yvette Marie Miller, M.D. Executive Medical Officer American Red Cross October 20, th Annual Great Lakes Cancer Nursing Conference Troy, MI

New Anticoagulants: When and Why Should I Use Them? Disclosures

Disclosure. New Agents for Treatment of DVT. Prevalence of DVT VTE. Normal Hemostasis 7/17/2015. Mark Oliver, MD, RVT, RPVI,FSVU

Anticoagulants for stroke prevention in atrial fibrillation Patient frequently asked questions

Genomic Analysis of Mature B-cell Malignancies

Abnormal Uterine Bleeding. Howard Herrell, MD FACOG

Guideline Statement for the Treatment of Disseminated Intravascular Coagulation

New Oral Anticoagulants

Heparin Induced Thrombocytopenia


Rheumatic Fever Vs. (?) Post Strep Reactive Arthritis ינואר 2009

Duration of Dual Antiplatelet Therapy After Coronary Stenting

University of Utah CME Statement

Platelet function defects

Prevention of Acute COPD exacerbations

Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction

Periodontal Screening and Recording: Early Detection of Periodontal Diseases

Enoxaparin for long term anticoagulation in patients unsuitable for oral anticoagulants

Abnormal Basic Coagulation Testing Laboratory Testing Algorithms

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

Now We Got Bad Blood: New Anticoagulant Reversal

Traveller s Thrombosis. Dr. Peter Verhamme Vascular Medicine and Haemostasis UZ Leuven

Canine Distemper Virus

How To Know If You Have A Bleeding Disorder

CF ATLANTA Research & Development Program at Emory University and Georgia Tech (CF@LANTA) Clinical & Translational Research Core

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Testing antiplatelet therapy

Bleeding Disorders What Every ER RN Should KNOW! Sherry Purcell, RN Hemophilia Nurse Specialist/EMERGENCY RN Kingston General Hospital

Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab)

New anticoagulants: Monitoring or not Monitoring? Not Monitoring

Instructions for Use

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

Antiplatelet and anticoagulation treatment of patients undergoing carotid and peripheral artery angioplasty

Causes of Anemia in Patients with Heart Failure. Adriaan Voors, MD, PhD, Cardiologist Professor of Cardiology, UMC Groningen, Netherlands

List of publications

Abnormal Uterine Bleeding: Simple evaluation and management in premenopausal women

Schlüsselwörter Thrombozytenfunktion, klinische Anwendung, Antithrombotika, Blutungsrisiko

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Transcription:

Platelet function in thrombocytopenia Mark Roest Synapse Research Institute, Maastricht

No Disclosures

Trauma

1. Adhesion

2. Activation and Aggregation

3. Stable Aggregate Formation

4. Repair

Platelet Disorder Mucocutaneous bleeding low platelet count and/or dysfunction epistaxis Prolonged bleeding Heavy Bruising Petechiae Gastro-intestinal bleeding Oral bleeding Bleeding after tooth extraction Menorrhagia

Thrombocytopenia: Current guidelines Platelet counts < 10*10 9 platelets / L transfusion Platelet counts > 10*10 9 platelets / L no transfusion We need platelet function testing in addition to platelet counts Those patients don t need transfusion if the function of the remaining platelets is still adequate Those patients need transfusion if the function of the remaining platelets is not adequate

Platelet function monitoring in diagnostic settings Bleeding time PFA-100 ROTEM TEG verifynow multiplate LTA These tests are based on platelet aggregation or platelet deposition This is highly dependent on platelete concentration

Platelet function tests Bleeding Time and PFA: Only for VW diseases and platelet adhesion ROTEM: Only for prediction post surgery bleeding? VASP: Only for P2Y12 inhibitor monitoring VerifyNOW: Only for P2Y12 inhibitors and aspirin monitoring Multiplate: Potentially interesting no progression Aggregometry: Gold standard disappearing Whole blood platelet function flow cytometry

SSC Count Count Platelet Function Agonist Anti-P-selectin P-selectine αiibβ3 10 5 Anti-fibrinogeen 10 4 10 3 10 2 10 10 10 2 10 3 10 4 FSC 10 5 10 10 2 10 3 10 4 10 5 CD62P-PE 10 10 2 10 3 10 4 10 5 CD62P-PE

Platelet Activation Test (PACT) TRAP ADP Thrombin receptor (PAR1) ADP receptor (P 2 Y 12 ) Blood Platelet Collagen receptor (GPVI) CRP P-selectin (MFI) Flow Cytometry ADP ( 0.01 0.03 0.12 0.49 1.95 7.81 31.3 125 TRAP ( M) 0.04 0.15 0.61 2.44 9.76 39.1 156 625 CRP(ng/mL) 0.15 0.61 2.44 9.76 39.1 156 625 2500 P-selectin (MFI) Master Mix P-selectin (MFI)

Platelet Activation Test (PACT) 1. Platelet function in stored concentrates 2. Platelet function in blood of patients with thrombocytopenia

Platelet Function in stored concentrates (1) P-selectin expression Day 2 6 8 10 0 2 6 8 10 Time Days Middelburg RA, Roest M, Ham J, Coccoris M, Zwaginga JJ, van der Meer PF. Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion. 2013 Aug;53(8):1780-7.

Platelet Function in stored concentrates (2) 0 2 3 4 5 6 7 8 9 10 Time Days Cécile H. Kicken, Mark Roest, Yvonne M. Henskens, Bas de Laat, Dana Huskens. Monitoring platelet concentrates, submited

Platelet Function in stored concentrates (3) 0 5 6 7 10 11 15 Time Days P-selectin expression (AU) 10000 8000 6000 4000 2000 SFLLRN 0 5 10 Day a IIb b 3 activation (AU) 4000 3000 2000 1000 SFLLRN 0 5 10 Day P-selectin expression (AU) 5000 4000 3000 2000 1000 CRP 0 5 10 Day a IIb b 3 activation (AU) 5000 4000 3000 2000 1000 CRP 0 5 10 Day P-selectin expression (AU) 2000 1500 1000 500 ADP 0 5 10 Day a IIb b 3 activation (AU) 800 600 400 200 ADP 0 5 10 Day P-selectin expression (AU) 2500 2000 1500 1000 500 0-500 U46619 10 Day a IIb b 3 activation (AU) 250 200 150 100 50 U46619 0 5 10 Day Roest M, van Holten TC, Fleurke GJ, Remijn JA. Platelet Activation Test in Unprocessed Blood (Pac-t-UB) to Monitor Platelet Concentrates and Whole Blood of Thrombocytopenic Patients. Transfus Med Hemother. 2013 Apr;40(2):117-25.

Platelet Activation Test (PACT) 1. Platelet function in stored concentrates 2. Platelet function in blood of patients with thrombocytopenia

Platelet function in blood of patients with thrombocytopenia Healthy controls (n=10) Patients with thrombocytopenia (n=11) Bikker A, Bouman E, Sebastian S, Korporaal SJ, Urbanus RT, Fijnheer R, Boven LA, Roest M. Functional recovery of stored platelets after transfusion. Transfusion. 2016 May;56(5):1030-7.

P -s e le c tin e x p re s s io n (% ) 1 5 0 P A R - 1 P A R - 4 C R P A D P 1 0 0 5 0 0 5 1 0 2 0 3 0 4 0 5 0 6 0 7 0 2 0 0 P la te le t c o u n t (x 1 0 9 /L ) Birol Batman, Esther R van Bladel, Mariska van Hamersveld, Pieternel CM Pasker-de Jong, Suzanne JA Korporaal, Rolf T Urbanus, Mark Roest, Leonie A Boven, Rob Fijnheer. Agonist induced platelet reactivity predicts bleeding in hemato-oncological patient, submited

Platelet function pre- and post-transfusion Bikker A, Bouman E, Sebastian S, Korporaal SJ, Urbanus RT, Fijnheer R, Boven LA, Roest M. Functional recovery of stored platelets after transfusion. Transfusion. 2016 May;56(5):1030-7.

M F I P -s e le c tin (u n its ) Platelet function, platelet count and bleeding risk Platelet function and bleeding Platelet count and bleeding P A R 1 -A P P A R 4 -A P 4 3 2 1 * M F I P -s e le c tin (u n its ) 3 2 1 ** 0 0 N o B le e d in g B le e d in g N o B le e d in g B le e d in g Birol Batman, Esther R van Bladel, Mariska van Hamersveld, Pieternel CM Pasker-de Jong, Suzanne JA Korporaal, Rolf T Urbanus, Mark Roest, Leonie A Boven, Rob Fijnheer. Agonist induced platelet reactivity predicts bleeding in hemato-oncological patient, submited

ITP Auto-antibodies to platelets Increased Platelet Consumption Low Platelet Counts ITP has a heterogeneous pathogenesis and the phenotype does not necessarily correlate with platelet counts Platelet Function Testing to customize the therapy?

Platelet function testing in ITP van Bladel, Laarhoven AG, van der Heijden LB, Heitink-Pollé KM, Porcelijn L, van der Schoot CE, de Haas M, Roest M, Vidarsson G, de Groot PG, Bruin MCFunctional platelet defects in children with severe chronic ITP as tested with 2 novel assays applicable for low platelet counts. Blood 2014;123:1556-63.

Conclusion PACT can be used to monitor platelet function in concentrates PACT can be used to measure platelet function in thrombocytopenia Upcoming studies will show if this test can be used to customize the treatment of patients with thrombocytopenia

Mark Roest Philip de Groot Dana Huskens Bas de Laat Rob Fijnheer Leonie Boven Esther van Bladel Birol Batman Rolf Urbanus Suzanne Korporaal Albert Huisman Angela Bikker Jaap Jan Zwaginga Rutger Middelburg Jasper Remijn